| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.6 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |